<DOC>
	<DOCNO>NCT00607997</DOCNO>
	<brief_summary>This study evaluate overall remission rate treatment voreloxin Injection patient least 60 year age previously untreated AML</brief_summary>
	<brief_title>Study Voreloxin Older Patients With Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>Other objective study include : 1 . Safety 2 . Survival 3 . Pharmacokinetics 4 . Evaluate potential biomarkers</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1 . At least 60 year age diagnosis previously untreated AML ( either de novo antecedent hematologic disorder therapy relate AML ) 2 . At least 20 % blast BM biopsy aspirate 3 . ECOG performance status 0,1 , 2 4 . Adequate cardiac , renal liver function 1 . Uncontrolled DIC 2 . Active central nervous system involvement AML 3 . Requiring hemodialysis peritoneal dialysis 4 . Some prior history heart attack stroke ( depend long ago event occur )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Elderly</keyword>
	<keyword>Hematologic</keyword>
	<keyword>Blood</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignancy</keyword>
	<keyword>SNS-595</keyword>
	<keyword>Sunesis</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Older</keyword>
	<keyword>voreloxin</keyword>
	<keyword>reveal-1</keyword>
</DOC>